STOCK TITAN

Ginkgo Bioworks Holdings Inc - DNA STOCK NEWS

Welcome to our dedicated news page for Ginkgo Bioworks Holdings (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ginkgo Bioworks Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ginkgo Bioworks Holdings's position in the market.

Rhea-AI Summary
Ginkgo Bioworks (DNA) Expects to meet 2023 new program and revenue guidance ranges, ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business. Strong growth among blue chip pharma and biotech customers including Pfizer, Novo Nordisk, Merck and Boehringer Ingelheim. Preliminary performance updates for the year ended December 31, 2023, include Total revenue of $250 – $260 million, with Cell Engineering revenue expected to be within the previously disclosed guidance range of $145 – $150 million, and Biosecurity revenue in line with the previously disclosed guidance of up to $110 million. Ginkgo also expects 80-85 new Cell Programs added to the platform in 2023, signed or advanced several major new biopharma programs, and ended 2023 with nearly $950 million of cash and cash equivalents. The company plans to report fourth quarter and full year 2023 financial results in February 2024, at which time it intends to provide its outlook for full year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) forms Biopharma Advisory Board with experts from the biopharmaceutical industry. The council will provide insight into the development of Ginkgo's core platform service offerings, including target discovery, drug discovery, optimization, and manufacturing. Notable members include Norbert Bischofberger, Jeff Legos, John Maraganore, Paolo Martini, Mark McCamish, and Christi Shaw.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
management
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) successfully completed a gene therapy collaboration with Biogen, enhancing the productivity of Biogen's AAV production platform. The collaboration aimed to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors, achieving their goals of enhancing AAV production titers. This collaboration signifies the potential for significant improvements in therapeutics discovery and manufacturing, showcasing the power of a platform-based approach to biological R&D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) CEO Jason Kelly to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.78%
Tags
none
-
Rhea-AI Summary
OneOne Biosciences (NYSE: DNA) partners with Ginkgo Bioworks to develop agricultural microbial solutions, focusing on nitrogen fixation. The partnership aims to leverage Ginkgo's expertise and infrastructure to accelerate OneOne's research and product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
partnership
-
Rhea-AI Summary
FGen AG (NYSE: DNA) awarded funding for sustainable milk protein production using CO2 and electricity
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.29%
Tags
none
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) has been awarded funding through the U.S. Department of Energy's (DOE) Bioenergy Technologies Office (BETO) to develop a new approach to algal crop protection, inspired by integrated pest management strategies used for terrestrial crops. This project aims to improve algal biotechnology to enable increased production of affordable biofuels and bioproducts from atmospheric CO2 at large scales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.29%
Tags
none
-
Rhea-AI Summary
GreenLab (NYSE: DNA) partners with Ginkgo Bioworks to develop an enzymatic solution to degrade PFAS, a major environmental and health concern. The project aims to create the first-ever commercially deployed enzymatic solution for PFAS degradation, leveraging Ginkgo's Enzyme Services and Allonnia's partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.29%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) receives a grant from the Bill & Melinda Gates Foundation to develop a live cell therapeutic that can produce antibodies to fight HIV and malaria. The company will focus on creating a prototype engineered cell line that can express antibodies for the treatment of HIV and/or malaria via an implantable device, potentially leading to long-term and cost-effective treatments for these diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.27%
Tags
none
Rhea-AI Summary
Arbor Biotechnologies, a genetic medicines company (NYSE: DNA), collaborates with Ginkgo Bioworks to optimize precision gene editors, leveraging Ginkgo's R&D services to accelerate the advancement of genetic editing technologies for therapeutic applications. Arbor's unique gene editors have significant therapeutic potential due to their protospacer adjacent motifs, varied cut types, smaller editing technology, and high specificity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Stock Data

2.50B
1.12B
6.74%
83.72%
12.18%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Boston

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.